Report : Asia Pacific Breast Cancer Screening Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Test Type (Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test),End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Country.
HospitalsSegment to DominateAsia Pacific Breast Cancer Screening MarketDuring 2020–2027
According to a new market research study on “Asia PacificBreast Cancer Screening MarketForecast to 2027 –by Test Type andEndUser,”the market is projectedto reach US$ 1,120.77 millionby2027 from US$ 798.57 millionin 2019. The market is estimated to grow at a CAGR of 5.4% from 2020 to 2027.The report provides trends prevailing in the Asia Pacificbreast cancer screening marketalong with the drivers and restraints pertaining to the market growth.The growth of the Asia Pacific breast cancer screening market is attributed to the increasing investments for research in breast cancer management and growing breast cancer prevalence across Asia Pacific. However, the high cost associated with breast cancer screeninghinders the market growth.
The breast cancer screening market, by end user, is segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitalssegment held the largest share of the Asia Pacificmarket in 2019;moreover,it isanticipated to register the highest CAGR in the market during the forecast period. Hospitals offer diagnostic and treatment services for multiple indications. The team of doctors, nurses, and trained pathologist provide better treatments through proper diagnosis.
Koninklijke Philips N.V., Hologic, Inc., Becton, Dickinson and Company, Myriad Genetics, Inc., Siemens Healthcare AG, Exact Sciences Corporation, OncoCyte Corporation, POC Medical systems, DanaherCorporation, and General ElectricCompany are among the leading companies in the breast cancer screening market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2018, GE Healthcare announced the launch ofSerena Brightwhich claimed to be the first healthcare sector’s contrast-enhanced mammography solution for biopsy.
Asia PacificBreast Cancer Screening Market, By Country, 2019 (%)
The report segments the Asia Pacificbreast cancer screening market as follows:
By Test Type
- Blood Marker Test
- Imaging Test
- Genetic Test
- Immunohistochemistry Test
By EndUser
- Diagnostic Centers
- Hospitals
- Research Laboratories
- Cancer Institutes
By Country
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com